School of Biomedical Sciences, University of Nottingham, Medical School, Queen's Medical Centre, Nottingham, UK.
Br J Pharmacol. 2010 Jun;160(3):669-76. doi: 10.1111/j.1476-5381.2010.00703.x.
Recent studies suggest that the effects of cyclooxygenase-2 (COX-2) inhibition are mediated by cannabinoid receptor activation. However, some non-steroidal anti-inflammatory drugs inhibit the enzyme fatty acid amide hydrolase, which regulates levels of some endocannabinoids. Whether COX-2 directly regulates levels of endocannabinoids in vivo is unclear. Here, the effect of the COX-2 inhibitor nimesulide, which does not inhibit fatty acid amide hydrolase, on spinal nociceptive processing was determined. Effects of nimesulide on tissue levels of endocannabinoids and related compounds were measured and the role of cannabinoid 1 (CB(1)) receptors was determined.
Effects of spinal and peripheral administration of nimesulide (1-100 microg per 50 microL) on mechanically evoked responses of rat dorsal horn neurones were measured, and the contribution of the CB(1) receptor was determined with the antagonist AM251 (N-(piperidin-1-yl)-5-(-4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide), in anaesthetized rats. Effects of nimesulide on spinal levels of endocannabinoids and related compounds were quantified using liquid chromatography-tandem mass spectrometry.
Spinal, but not peripheral, injection of nimesulide (1-100 microg per 50 microL) significantly reduced mechanically evoked responses of dorsal horn neurones. Inhibitory effects of spinal nimesulide were blocked by the CB(1) receptor antagonist AM251 (1 microg per 50 microL), but spinal levels of endocannabinoids were not elevated. Indeed, both anandamide and N-oleoylethanolamide (OEA) were significantly decreased by nimesulide.
Although the inhibitory effects of COX-2 blockade on spinal neuronal responses by nimesulide were dependent on CB(1) receptors, we did not detect a concomitant elevation in anandamide or 2-AG. Further understanding of the complexities of endocannabinoid catabolism by multiple enzymes is essential to understand their contribution to COX-2-mediated analgesia.
最近的研究表明,环氧化酶-2(COX-2)抑制的作用是通过大麻素受体的激活来介导的。然而,一些非甾体抗炎药抑制调节某些内源性大麻素水平的脂肪酸酰胺水解酶。COX-2 是否直接调节体内内源性大麻素的水平尚不清楚。在这里,确定了 COX-2 抑制剂尼美舒利(不抑制脂肪酸酰胺水解酶)对脊髓伤害性感受处理的影响。测量了尼美舒利对组织内源性大麻素和相关化合物水平的影响,并确定了大麻素 1(CB1)受体的作用。
测量了尼美舒利(1-100μg/50μL)鞘内和外周给药对麻醉大鼠背角神经元机械诱发反应的影响,并使用拮抗剂 AM251(N-(哌啶-1-基)-5-(4-碘苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-甲酰胺)确定 CB1 受体的作用。使用液相色谱-串联质谱法定量分析尼美舒利对脊髓内源性大麻素和相关化合物水平的影响。
鞘内而非外周注射尼美舒利(1-100μg/50μL)显著降低背角神经元的机械诱发反应。脊髓尼美舒利的抑制作用被 CB1 受体拮抗剂 AM251(1μg/50μL)阻断,但脊髓内源性大麻素水平没有升高。事实上,尼美舒利显著降低了花生四烯酸乙醇酰胺(anandamide)和 N-油酰乙醇酰胺(OEA)的水平。
尽管尼美舒利通过 CB1 受体依赖阻断 COX-2 对脊髓神经元反应的抑制作用,但我们没有检测到 anandamide 或 2-AG 的伴随升高。进一步了解多种酶对内源性大麻素代谢的复杂性对于理解它们对 COX-2 介导的镇痛的贡献至关重要。